Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Endocrinology

Managing Non-Endocrine Complications

At a Glance

APS-1 can cause important non-endocrine problems, including chronic Candida infections, dental and skin changes, and inflammation of the lungs, liver, intestines, or kidneys. Prompt evaluation of warning symptoms and specialist monitoring help guide treatment.

While the hormone-related parts of APS-1 (APECED) often get the most attention, the condition also affects many other parts of the body. These “non-endocrine” symptoms can range from surface-level issues like skin and tooth changes to serious internal organ inflammation [1]. Managing these requires a specialized team that looks beyond just blood sugar and calcium levels [2].

Chronic Mucocutaneous Candidiasis (CMC)

The most common feature of APS-1 is CMC, a persistent or recurring yeast infection caused by Candida [3]. It most often affects the mouth (thrush), but it can also involve the esophagus, genitals, skin, and nails [1].

  • The Challenge of Resistance: Because CMC often requires long-term treatment with antifungal medications like fluconazole (an “azole”), the yeast can become less sensitive to the medicine over time [4]. If a standard treatment stops working, your doctor should perform a culture to identify the specific strain and test which antifungals it still responds to [5].
  • Cancer Surveillance: Long-standing CMC, especially in the mouth and esophagus, is associated with an increased risk of developing certain cancers later in life [6]. Regular dental and oral assessment according to an APECED-informed clinician is highly recommended. Any persistent white patches, sores that won’t heal, or difficulty swallowing must be evaluated promptly [6].

Ectodermal Manifestations: Skin, Hair, and Teeth

“Ectodermal” refers to tissues like skin and enamel that develop from the same early embryonic layer. In APS-1, these are frequently affected [7].

  • Enamel Hypoplasia: This causes permanent pitting, ridges, or yellow-brown discoloration of the teeth [8]. Because these teeth are more prone to cavities, specialized dental care is a necessity [9].
  • Skin and Hair: You may notice vitiligo (loss of skin pigment) or alopecia areata (patchy hair loss) [10]. While not life-threatening, they can be emotionally challenging and often occur alongside other symptoms [11].
  • Nail Dystrophy: Nails may become thickened, brittle, or discolored, sometimes due to Candida and sometimes due to the underlying autoimmune process [12].

Internal Organ Involvements

Some of the most serious complications of APS-1 occur when the immune system affects internal organs [13].

  • Autoimmune Pneumonitis: Inflammation of the lungs that can cause a dry cough or shortness of breath [13]. Routine chest CTs for completely asymptomatic patients are generally not universally recommended due to radiation exposure. However, pulmonary symptoms should prompt function testing and imaging selected by an experienced clinician [14].
  • Autoimmune Hepatitis: The immune system may affect the liver, leading to elevated liver enzymes or, in rare cases, liver failure [15]. Regular blood tests can catch this early [16].
  • Autoimmune Enteritis: This affects the intestines, leading to chronic diarrhea and malabsorption (the inability to absorb nutrients and medications properly) [17]. This can make managing other conditions, like hypoparathyroidism, much more difficult [18].
  • Renal (Kidney) Complications: Kidneys can be affected in two ways: nephrocalcinosis (calcium deposits caused by treatment for hypoparathyroidism) or tubulointerstitial nephritis (direct immune involvement in the kidney tissue) [19][20]. Both require careful monitoring of kidney function and blood pressure [20].

Systemic Immunomodulation

When organ inflammation (like severe pneumonitis or hepatitis) becomes dangerous, doctors may use medications that suppress the immune system [21].

  • Specialist-Directed Options: Medications such as mycophenolate mofetil, rituximab, or newer JAK inhibitors like ruxolitinib are sometimes utilized [21][7]. These are not a standard menu of treatments; they are highly individualized and often off-label.
  • Balancing Risks: While these drugs can help preserve organ function, they significantly increase the risk of serious infections and can worsen Candida [22]. For example, mycophenolate can sometimes cause intestinal inflammation (colitis) that mimics the disease itself [23]. Your care team will carefully assess your chronic candidiasis and infection risk before starting these therapies [24].

Common questions in this guide

Why might I need a fungal culture for recurring thrush with APS-1?
Chronic mucocutaneous candidiasis can become less responsive to fluconazole and other azole antifungals after long-term use. A culture with susceptibility testing identifies the Candida strain and shows which medicines are most likely to work.
Which breathing symptoms should prompt evaluation for APS-1 lung involvement?
A persistent dry cough or shortness of breath, including with light activity, should be discussed with a clinician. They may use pulmonary function tests and selected imaging; routine chest CT is not universally recommended for people without symptoms because of radiation exposure.
How are liver problems monitored in APS-1?
Autoimmune hepatitis may cause elevated AST and ALT levels and, rarely, liver failure. Regular liver blood tests can detect changes early, and a hepatologist may be involved when results or symptoms warrant specialist care.
Can APS-1 cause diarrhea and trouble absorbing nutrients or medicines?
Autoimmune enteritis can cause chronic diarrhea and malabsorption, meaning the intestines do not absorb nutrients or medications properly. These problems can make conditions such as hypoparathyroidism harder to manage, so changes in bowel habits should be evaluated.
What skin, hair, nail, and dental changes can occur with APS-1?
APS-1 may cause enamel defects, vitiligo, patchy hair loss, and thickened, brittle, or discolored nails. Enamel defects increase cavity risk, so regular assessment and specialized dental care may be needed.
How can APS-1 affect the kidneys?
Kidney problems may include calcium deposits related to hypoparathyroidism treatment or immune inflammation of kidney tissue. Kidney function and blood pressure should be monitored so the care team can identify problems early.
When are immune-suppressing medicines used for APS-1 complications?
For dangerous inflammation of organs such as the lungs or liver, specialists may consider medicines such as mycophenolate mofetil, rituximab, or ruxolitinib. These treatments are individualized and may be off-label; they can raise the risk of serious infections and worsen Candida infections.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have we performed a fungal culture and susceptibility test for my (or my child's) recent thrush to check for azole resistance?
  2. 2.Given the risk of lung issues, what symptoms should prompt me to request a pulmonary function test or imaging?
  3. 3.Are my liver enzymes (AST/ALT) being checked regularly, and what level would trigger a referral to a hepatologist?
  4. 4.How can we distinguish between autoimmune enteritis and potential side effects from my other medications?
  5. 5.Does the presence of enamel defects mean I should see a specialized pediatric or restorative dentist more frequently?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review.

    Sharifinejad N, Zaki-Dizaji M, Tebyanian S, et al.

    Expert review of clinical immunology 2021; (17(8)):807-817 doi:10.1080/1744666X.2021.1925543.

    PMID: 33957837
  2. 2

    Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED): Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

    Hamidi M, Kamrani M, Karami S, et al.

    Endocrine, metabolic & immune disorders drug targets 2026; doi:10.2174/0118715303511788260918112249.

    PMID: 42786839
  3. 3

    [Oral diseases in auto-immune polyendocrine syndrome type 1].

    Proust-Lemoine E, Guyot S

    Presse medicale (Paris, France : 1983) 2017; (46(9)):853-863 doi:10.1016/j.lpm.2017.05.029.

    PMID: 28683959
  4. 4

    Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1.

    Humbert L, Cornu M, Proust-Lemoine E, et al.

    Frontiers in immunology 2018; (9()):2570 doi:10.3389/fimmu.2018.02570.

    PMID: 30510552
  5. 5

    Persistence of Clonal Azole-Resistant Isolates of Candida albicans from a Patient with Chronic Mucocutaneous Candidiasis in Colombia.

    Ceballos-Garzon A, Wintaco-Martínez LM, Velez N, et al.

    Journal of global infectious diseases 2020; (12(1)):16-20 doi:10.4103/jgid.jgid_74_19.

    PMID: 32165797
  6. 6

    Head and Neck Malignancies in Autoimmune Polyendocrine Syndrome Type 1 (APS-1/APECED): A Scoping Review of Molecular Pathogenesis, Clinical Features, and Outcomes.

    Tarle M, Raguž M, Lukšić I

    International journal of molecular sciences 2025; (26(18)) doi:10.3390/ijms26188969.

    PMID: 41009535
  7. 7

    Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1.

    Lévy R, Escudier A, Bastard P, et al.

    Journal of clinical immunology 2023; (44(1)):5 doi:10.1007/s10875-023-01629-x.

    PMID: 38112858
  8. 8

    Case Report: Dental Findings Can Aid in Early Diagnosis of APECED Syndrome.

    Brenchley L, Ferré EMN, Schmitt MM, et al.

    Frontiers in dental medicine 2021; (2()) doi:10.3389/fdmed.2021.670624.

    PMID: 38148990
  9. 9

    A Rare Case of Autoimmune Polyendocrinopathy-candidiasis-ectodermal Dystrophy Syndrome: Dental Perspective on Diagnosis and Management.

    Tyagi R, Kalra N, Khatri A, et al.

    International journal of clinical pediatric dentistry 2023; (16(1)):139-146 doi:10.5005/jp-journals-10005-2496.

    PMID: 37020766
  10. 10

    Alopecia areata and occurrence of vitiligo and hypothyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients.

    Englander H, Ferré EMN, Schmitt MM, et al.

    Pediatric dermatology 2023; (40(5)):857-859 doi:10.1111/pde.15380.

    PMID: 37495514
  11. 11

    Cutaneous Manifestations in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED): A Comprehensive Review.

    Sandru F, Petca RC, Dumitrascu MC, et al.

    Biomedicines 2024; (12(1)) doi:10.3390/biomedicines12010132.

    PMID: 38255237
  12. 12

    Clinical Characteristics in the Longitudinal Follow-Up of APECED Syndrome in Southern Croatia-Case Series.

    Skrabic V, Skrabic I, Skrabic R, et al.

    Genes 2022; (13(4)) doi:10.3390/genes13040558.

    PMID: 35456364
  13. 13

    Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance.

    Ferré EMN, Break TJ, Burbelo PD, et al.

    Science translational medicine 2019; (11(495)) doi:10.1126/scitranslmed.aav5597.

    PMID: 31167928
  14. 14

    Fatal autoimmune pneumonitis requiring bilobectomy and omental flap repair in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

    Kubala SA, Do HM, Ferré EMN, et al.

    Respiratory medicine case reports 2021; (33()):101476 doi:10.1016/j.rmcr.2021.101476.

    PMID: 34401309
  15. 15

    APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort.

    Chascsa DM, Ferré EMN, Hadjiyannis Y, et al.

    Hepatology (Baltimore, Md.) 2021; (73(3)):1088-1104 doi:10.1002/hep.31421.

    PMID: 32557834
  16. 16

    Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

    Kisand K, Peterson P

    Journal of clinical immunology 2015; (35(5)):463-78 doi:10.1007/s10875-015-0176-y.

    PMID: 26141571
  17. 17

    Case Report: Severe Hypocalcemic Episodes Due to Autoimmune Enteropathy.

    Halabi I, Barohom MN, Peleg S, et al.

    Frontiers in endocrinology 2021; (12()):645279 doi:10.3389/fendo.2021.645279.

    PMID: 34194389
  18. 18

    Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.

    Akers H, Maxey L, Ashley K, et al.

    JBMR plus 2026; (10(9)):ziag114 doi:10.1093/jbmrpl/ziag114.

    PMID: 42614145
  19. 19

    Renal disorders in Autoimmune Polyendocrinopathy Candidiasis Ectodermal dystrophy (APECED): a systematic review.

    Shafiei M, Hosseini S, Ghadimi S, et al.

    BMC pediatrics 2025; (25(1)):139 doi:10.1186/s12887-025-05458-2.

    PMID: 40000975
  20. 20

    Autoimmune polyglandular syndrome type I can have significant kidney disease in children including recurrence in renal allograft - a report of two cases.

    Gwertzman R, Corey H, Roberti I

    Clinical nephrology 2016; (85(6)):358-62 doi:10.5414/CN108782.

    PMID: 27142200
  21. 21

    AIRE Gene Mutation Presenting at Age 2 Years With Autoimmune Retinopathy and Steroid-Responsive Acute Liver Failure: A Case Report and Literature Review.

    Sakaguchi H, Mizuochi T, Haruta M, et al.

    Frontiers in immunology 2021; (12()):687280 doi:10.3389/fimmu.2021.687280.

    PMID: 34122451
  22. 22

    Infections in the monogenic autoimmune syndrome APECED.

    Oikonomou V, Break TJ, Gaffen SL, et al.

    Current opinion in immunology 2021; (72()):286-297 doi:10.1016/j.coi.2021.07.011.

    PMID: 34418591
  23. 23

    Mycophenolate-Induced Colitis in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.

    Schmitt MM, Ferré EMN, De Melo MS, et al.

    JPGN reports 2021; (2(4)) doi:10.1097/pg9.0000000000000131.

    PMID: 35425944
  24. 24

    Case report: Virus-induced hemophagocytic lymphohistiocytosis in a patient with APECED.

    Boyarchuk O, Dyvonyak O, Hariyan T, Volokha A

    Frontiers in pediatrics 2023; (11()):1086867 doi:10.3389/fped.2023.1086867.

    PMID: 36873640

This page is for informational purposes only and does not constitute medical advice. Your care team, including endocrinology, dental, and organ specialists, should interpret symptoms, test results, and treatment risks for you or your child.

Get notified when new evidence is published on Autoimmune polyendocrinopathy type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.